Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||MGC018||Case Reports/Case Series||Actionable||In a Phase I/II trial, MGC018 treatment resulted in a 29.4% decrease of target lesion in a patient with metastatic castrate-resistant prostate cancer (J Clin Oncol 38: 2020 (suppl; abstr 3071); NCT03729596).||detail...|
|PubMed Id||Reference Title||Details|
|Preliminary dose escalation results from a phase I/II, first-in-human study of MGC018 (anti-B7-H3 antibody-drug conjugate) in patients with advanced solid tumors.||Full reference...|